全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Candida albicans Fungaemia following Traumatic Urethral Catheterisation in a Paraplegic Patient with Diabetes Mellitus and Candiduria Treated by Caspofungin

DOI: 10.1155/2013/693480

Full-Text   Cite this paper   Add to My Lib

Abstract:

A 58-year-old paraplegic male, with long-term indwelling urethral catheter, developed catheter block. The catheter was changed, but blood-stained urine was drained intermittently. A long segment of the catheter was seen lying outside his penis, which indicated that the balloon of Foley catheter had been inflated in urethra. The misplaced catheter was removed and a new catheter was inserted correctly. Gentamicin 160?mg was given intravenously; meropenem 1 gram every eight hours was prescribed; antifungals were not given. Twenty hours later, this patient developed distension of abdomen, tachycardia, and hypotension; he was not arousable. Computed tomography of abdomen revealed inflamed uroepithelium of right renal pelvis and ureter, 4?mm lower ureteric calculus with gas in right ureter proximally, and vesical calculus containing gas in its matrix. Urine and blood culture yielded Candida albicans. Identical sensitivity pattern of both isolates suggested that the source of the bloodstream infection was most likely urine. Both isolates formed consistently high levels of biofilm formation in vitro as assessed using a biofilm biomass stain, and high levels of resistance to voriconazole were observed. Both amphotericin B and caspofungin showed good activity against the biofilms. HbA1c was 111?mmol/mol. This patient was prescribed human soluble insulin and caspofungin 70?mg followed by 50?mg daily intravenously. He recovered fully from candidemia. 1. Introduction Candidal colonisation of mucosal sites ordinarily poses no threat to the health of the host. Problems develop when the body’s defenses are abridged as occurs with diabetes mellitus, human immunodeficiency virus infection, neutropenia, and immunosuppression accompanying organ transplantation or when patients undergo certain procedures, such as bladder catheterisation or urologic surgery. Breaches in defense allow increased colonisation of mucosal surfaces and sometimes candidemia, in which case the organism can be carried to the kidneys. These predisposing conditions permit the survival of blood-borne or locally invasive yeast in sufficient numbers to evade the local or systemic immunity [1]. Medical devices such as stents and catheters have been shown to support colonisation and biofilm formation by Candida spp. [2]. The Candida biofilm lifestyle results in antifungal drug resistance and protection of the fungus from host defenses [3]. Candidemia is frequently associated with the biofilm growth of Candida organisms on medical devices such as a venous catheter or urinary catheter. In mice infected with

References

[1]  J. F. Fisher, K. Kavanagh, J. D. Sobel, C. A. Kauffman, and C. A. Newman, “Candida urinary tract infection: pathogenesis,” Clinical Infectious Diseases, vol. 52, supplement 6, pp. S437–S451, 2011.
[2]  G. Ramage, J. P. Martínez, and J. L. López-Ribot, “Candida biofilms on implanted biomaterials: a clinically significant problem,” FEMS Yeast Research, vol. 6, no. 7, pp. 979–986, 2006.
[3]  G. Ramage and C. Williams, “Clinical importance of fungal biofilms,” in Advances in Applied Microbiology, G. Gadd, Ed., pp. 38–62, Elsevier, New York, NY, USA, 2013.
[4]  F. Hasan, I. Xess, X. Wang, N. Jain, and B. C. Fries, “Biofilm formation in clinical Candida isolates and its association with virulence,” Microbes and Infection, vol. 11, no. 8-9, pp. 753–761, 2009.
[5]  M. Tumbarello, B. Fiori, E. M. Trecarichi et al., “Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital,” PLoS ONE, vol. 7, no. 3, Article ID e33705, 2012.
[6]  D. P. Bartkowski and J. R. Lanesky, “Emphysematous prostatitis and cystitis secondary to Candida albicans,” Journal of Urology, vol. 139, no. 5, pp. 1063–1065, 1988.
[7]  C. G. Pierce, P. Uppuluri, A. R. Tristan et al., “A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing,” Nature Protocols, vol. 3, no. 9, pp. 1494–1500, 2008.
[8]  G. Ramage, K. Vande Walle, B. L. Wickes, and J. L. López-Ribot, “Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 9, pp. 2475–2479, 2001.
[9]  B. S. Ang, A. Telenti, B. King, J. M. Steckelberg, and W. R. Wilson, “Candidemia from a urinary tract source: microbiological aspects and clinical significance,” Clinical Infectious Diseases, vol. 17, no. 4, pp. 662–666, 1993.
[10]  N. Toshikuni, K. Ujike, T. Yanagawa et al., “Candida albicans endophthalmitis after extracorporeal shock wave lithotripsy in a patient with liver cirrhosis,” Internal Medicine, vol. 45, no. 22, pp. 1327–1332, 2006.
[11]  S. M. Beck, D. S. Finley, and L. A. Deane, “Fungal urosepsis after ureteroscopy in cirrhotic patients: a word of caution,” Urology, vol. 72, no. 2, pp. 291–293, 2008.
[12]  A. Hassner, Y. Kletter, D. Shlag, M. Yedvab, M. Aronson, and S. Shibolet, “Impaired monocyte function in liver cirrhosis,” The British Medical Journal, vol. 282, no. 6272, pp. 1262–1263, 1981.
[13]  D. Record, “Fluconazole,” in Clinical and Research Information on Drug-Induced Liver Injury, United States National Library of Medicine, 2013, http://livertox.nih.gov/Fluconazole.htm.
[14]  G. Ramage, R. Rajendran, L. Sherry, and C. Williams, “Fungal biofilm resistance,” International Journal of Microbiology, vol. 2012, Article ID 528521, 14 pages, 2012.
[15]  J. Chandra, D. M. Kuhn, P. K. Mukherjee, L. L. Hoyer, T. McCormick, and M. A. Ghannoum, “Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance,” Journal of Bacteriology, vol. 183, no. 18, pp. 5385–5394, 2001.
[16]  G. Ramage, A. Jose, L. Sherry, D. F. Lappin, B. Jones, and C. Williams, “Liposomal amphotericin B displays rapid dose-dependent activity against Candida albicans biofilms,” Antimicrobial Agents and Chemotherapy, vol. 57, no. 5, pp. 2369–2371, 2013.
[17]  M. Tumbarello, B. Posteraro, E. M. Trecarichi et al., “Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia,” Journal of Clinical Microbiology, vol. 45, no. 6, pp. 1843–1850, 2007.
[18]  E. M. Kojic and R. O. Darouiche, “Candida infections of medical devices,” Clinical Microbiology Reviews, vol. 17, no. 2, pp. 255–267, 2004.
[19]  G. Ramage, K. Vande Walle, S. P. Bachmann, B. L. Wickes, and J. L. López-Ribot, “In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies,” Antimicrobial Agents and Chemotherapy, vol. 46, no. 11, pp. 3634–3636, 2002.
[20]  D. M. Kuhn, T. George, J. Chandra, P. K. Mukherjee, and M. A. Ghannoum, “Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins,” Antimicrobial Agents and Chemotherapy, vol. 46, no. 6, pp. 1773–1780, 2002.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133